Mylan Laboratories Inc. Fourth Quarter Earnings Sneak Peek
S&P 500 (NYSE:SPY) component Mylan Laboratories, Inc. (NASDAQ:MYL) will unveil its latest earnings on Tuesday, February 21, 2012. Mylan is a global pharmaceutical company that develops, licenses, manufactures, markets, and distributes pharmaceuticals and active pharmaceutical ingredients.
Mylan Laboratories, Inc. Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for profit of 50 cents per share, a rise of 11.1% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 49 cents. Between one and three months ago, the average estimate moved up. It has been unchanged at 50 cents during the last month. For the year, analysts are projecting net income of $2 per share, a rise of 24.2% from last year.
Past Earnings Performance: The company is looking to make a streak of three quarters of beating estimates. Last quarter, it beat expectations by reporting profit of 55 cents per share, and the previous quarter, it had net income of 52 cents.
Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?
Wall St. Revenue Expectations: On average, analysts predict $1.55 billion in revenue this quarter, a rise of 8.4% from the year-ago quarter. Analysts are forecasting total revenue of $6.15 billion for the year, a rise of 12.8% from last year’s revenue of $5.45 billion.
Analyst Ratings: 11 out of 18 analysts surveyed (61.1%) have a buy rating on Mylan Laboratories. This is below the mean analyst rating of 10 competitors, which average 64.8% buy ratings.
A Look Back: In the third quarter, profit rose 9.4% to $156.7 million (36 cents a share) from $143.2 million (33 cents a share) the year earlier, exceeding analyst expectations. Revenue rose 16.3% to $1.58 billion from $1.36 billion.
The company has seen net income rise in three consecutive quarters. Net income rose 69.8% in the second quarter and 8.7% in the first quarter.
For four quarters in a row, revenue has increased. Revenue rose 15% in the second quarter from the year earlier, climbed 12.1% in the first quarter from the year-ago quarter and 6.1% in the fourth quarter of the last fiscal year.
Stock Price Performance: Between November 17, 2011 and February 15, 2012, the stock price rose $5.26 (29.4%), from $17.90 to $23.16. The stock price saw one of its best stretches over the last year between June 22, 2011 and July 1, 2011, when shares rose for eight straight days, increasing 9.3% (+$2.12) over that span. It saw one of its worst periods between April 27, 2011 and May 6, 2011 when shares fell for eight straight days, dropping 5.3% (-$1.33) over that span.
(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)
Don’t Miss These Additional Hot Stories:
To contact the reporter on this story: Derek Hoffman at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com